Evidence map›Paper›PMID 37568921›Full record

ArticleDiagnostics (Basel, Switzerland)2023

Association of the

Diana G Rogel-Ayala, José Esteban Muñoz-Medina, Valeria Dejanira Vicente-Juárez, Patricia Grether-González, Deneb Algedi Morales-Barquet, Alfonso de Jesús Martínez-García, María Olga Leticia Echaniz-Aviles, Rosalba Sevilla-Montoya, Alejandro Martínez-Juárez, Jazmin Artega-Vázquez and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Diana G Rogel-AyalaReproductive and Perinatal Health Research Department, National Institute of Perinatology, Mexico City 11000, Mexico.
José Esteban Muñoz-MedinaQuality of Supplies and Specialized Laboratories Coordination, Mexican Social Security Institute, Mexico City 37320, Mexico.
Valeria Dejanira Vicente-JuárezReproductive and Perinatal Health Research Department, National Institute of Perinatology, Mexico City 11000, Mexico.
Patricia Grether-GonzálezABC Medical Center, Santa Fe, Mexico City 05348, Mexico.
Deneb Algedi Morales-BarquetNeonatal Intensive Care Unit, National Institute of Perinatology, Mexico City 11000, Mexico.
Alfonso de Jesús Martínez-GarcíaFetal Maternal Medicine Department, National Institute of Perinatology, Mexico City 11000, Mexico.
María Olga Leticia Echaniz-AvilesNewborn Intermediate Care Unit, National Institute of Perinatology, Mexico City 11000, Mexico.
Rosalba Sevilla-MontoyaReproductive and Perinatal Health Research Department, National Institute of Perinatology, Mexico City 11000, Mexico.
Alejandro Martínez-JuárezCellular Physiology Department, National Institute of Perinatology, Mexico City 11000, Mexico.
Jazmin Artega-VázquezDepartment of Genetics, National Institute of Medical Science and Nutrition, Mexico City 14080, Mexico.
Javier Angeles-MartínezSpecialized Laboratories Division, Mexican Social Security Institute, Mexico City 06700, Mexico.ORCID 0000-0001-5405-0482
Gilberto Vargas-AlarcónDepartment of Molecular Biology, National Institute of Cardiology, Mexico City 14080, Mexico.ORCID 0000-0001-7916-5163
Alberto Hidalgo-BravoGenomics Medicine Department, National Institute of Rehabilitation, Mexico City 14610, Mexico.ORCID 0000-0003-2506-8784
Irma Eloisa Monroy-MuñozReproductive and Perinatal Health Research Department, National Institute of Perinatology, Mexico City 11000, Mexico.ORCID 0000-0001-8737-8935
Instituto Nacional de Perinatología · MXMexican Social Security Institute · MXCentro Médico ABC · MXInstituto Nacional de Cardiología · MXNational Institute of Genomic Medicine · MX

Funding

National Institute of Perinatology 212250-3140-11105-01-16.
6 · The paper itself

Abstract

Patent ductus arteriosus (PDA) is frequent in preterm newborns, and its incidence is inversely associated with the degree of prematurity. The first choice of pharmacological treatment is ibuprofen. Several genes, including

Indexed as

EPAS1 polymorphismibuprofenpatent ductus arteriosuspharmacological closurepreterm infants

Identifiers

PMID37568921
PMCPMC10417126
OpenAlexW4385461640

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.